Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 18;12(2):473.
doi: 10.3390/cancers12020473.

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

Manuela Tiako Meyo  1   2   3 , Anne Jouinot  3   4 , Etienne Giroux-Leprieur  5 , Elizabeth Fabre  6 , Marie Wislez  7 , Marco Alifano  8 , Karen Leroy  9 , Pascaline Boudou-Rouquette  3 , Camille Tlemsani  3 , Nihel Khoudour  1 , Jennifer Arrondeau  3 , Audrey Thomas-Schoemann  2   3 , Hélène Blons  10 , Audrey Mansuet-Lupo  9 , Diane Damotte  9 , Michel Vidal  1   2 , François Goldwasser  3   11 , Jérôme Alexandre  3   4   11 , Benoit Blanchet  1   2
Affiliations

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

Manuela Tiako Meyo et al. Cancers (Basel). .

Abstract

A large interindividual variability has been observed in anti Programmed cell Death 1 (anti-PD1) therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 (sPD-1), soluble Programmed cell Death Ligand 1 (sPD-L1), Vascular Endothelial Growth Factor A (VEGFA), soluble CD40 ligand (sCD40L) and soluble CD44 (sCD44), with survival in nivolumab-treated metastatic non-small cell lung cancer (NSCLC) patients. Plasma biomarkers were assayed at baseline and after two cycles of nivolumab. A cut-off of positivity for sPD-1, sPD-L1 and sCD40L expressions was defined as a plasma level above the lower limit of quantification. Baseline sPD-1 and sPD-L1 levels were subsequently analyzed in a control group of EGFR-mutated (Epidermal Growth Factor Receptor) NSCLC patients. Association between survival and biomarkers was investigated using Cox proportional hazard regression model. Eighty-seven patients were included (51 nivolumab-treated patients, 36 in EGFR-mutated group). In nivolumab group, baseline sPD-1, sPD-L1 and sCD40L were positive for 15(29.4%), 27(52.9%) and 18(50%) patients, respectively. We defined a composite criteria (sCombo) corresponding to sPD-1 and/or sPD-L1 positivity for each patient. In nivolumab group, baseline sCombo positivity was associated with shorter median progression-free survival (PFS) (78 days 95%CI (55-109) vs. 658 days (222-not reached); HR: 4.12 (1.95-8.71), p = 0.0002) and OS (HR: 3.99(1.63-9.80), p = 0.003). In multivariate analysis, baseline sCombo independently correlated with PFS (HR: 2.66 (1.17-6.08), p = 0.02) but not OS. In EGFR-mutated group, all patients were baseline sCombo positive; therefore this factor was not associated with survival. After two cycles of nivolumab, an increased or stable sPD-1 level independently correlated with longer PFS (HR: 0.49, 95%CI (0.30-0.80), p = 0.004) and OS (HR: 0.39, 95%CI (0.21-0.71), p = 0.002). VEGFA, sCD40L and sCD44 did not correlate with survival. We propose a composite biomarker using sPD-1and sPDL-1 to predict nivolumab efficacy in NSCLC patients. A larger validation study is warranted.

Keywords: Immune checkpoint inhibitors; NSCLC; PD-1; biomarkers; nivolumab.

PubMed Disclaimer

Conflict of interest statement

B.B. has served on advisory boards and received honoraria AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Leo Pharma and Pfizer. D.D. has received fees for consulting and educational activities from Bristol-Myers Squibb, Merck Sharp and Dohme, AstraZeneca Medimmune, Roche/Genentech. F.G. has received travel accommodation and research grant from Bristol-Myers Squibb. J.Ale. has received grants and honoraria from AstraZeneca, Roche/Genentech, Novartis, Ipsen, and Jansen. P.B.-R. has served on advisory board for and received honoraria from Bristol-Myers Squibb. M.W. has received fees for consulting, advisory board and educational activities from Boehringer Ingelheim, Roche, MSD, Amgen, BMS, Astra Zeneca; and her institution received clinical trials support from AstraZeneca. All other authors (M.T.M., A.J., E.G.-L., E.F., M.A., K.L., C.T., N.K., J.Arr., A.T.-S., H.B., A.M.-L., M.V.) have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Flow chart.
Figure 2
Figure 2
Kaplan–Meier estimates of patients’ (A) progression-free survival and (B) overall survival according to sCombo status.
Figure 3
Figure 3
Kaplan–Meier estimates of patients’ (A) progression-free survival and (B) overall survival according to sPD-1 evolution between baseline and day 28. Tick marks indicate censoring of data.
Figure 4
Figure 4
Three theoretical interaction between sPD-1, sPD-L1 and the tumour and its environment, leading to resistance to anti-PD1 therapies. sPD-1/ sPD-L1: soluble PD-1/PD-L1; mPD-1/mPD-L1: membrane-bound PD-1/ PD-L1.
See this image and copyright information in PMC

References

    1. Alexandrov L.B., Ju Y.S., Haase K., Van Loo P., Martincorena I., Nik-Zainal S., Totoki Y., Fujimoto A., Nakagawa H., Shibata T., et al. Mutational signatures associated with tobacco smoking in human cancer. Science. 2016;354:618–622. doi: 10.1126/science.aag0299. - DOI - PMC - PubMed
    1. Chen D.S., Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 2013;39:1–10. doi: 10.1016/j.immuni.2013.07.012. - DOI - PubMed
    1. Planchard D., Popat S., Kerr K., Novello S., Smit E.F., Faivre-Finn C., Mok T.S., Reck M., Van Schil P.E., Hellmann M.D., et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †. Ann Oncol. 2018;29:192–237. doi: 10.1093/annonc/mdy275. - DOI - PubMed
    1. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. doi: 10.1038/nrc3239. - DOI - PMC - PubMed
    1. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., Chow L.Q., Vokes E.E., Felip E., Holgado E., et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2015;373:1627–1639. doi: 10.1056/NEJMoa1507643. - DOI - PMC - PubMed